← Leaderboards
Abdolmohamad Rostami
Thomas Jefferson University
$26,076,182
Attributed
$26,076,182
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,831,720 · 20
By mechanism
R01$23,788,748 · 12
U19$7,272,277 · 5
R56$387,500 · 1
P01$383,195 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Stephen D Miller · Northwestern University$23,969,272
- Fred D Lublin · Mount Sinai School Of Medicine Of Nyu$22,560,310
Research focus
Multiple SclerosisCellsCytokineExperimental Autoimmune EncephalomyelitisAnimal ModelPlayAutoimmune DiseasesProductionT-LymphocyteInflammatoryInterleukin-10BasePathogenesisImmune ResponsePathogenicityMediatingAntigensCd4 Positive T LymphocytesResponseIn VivoInflammationAutoimmunityGranulocyte-Macrophage Colony-Stimulating FactorDemyelinations
Grant awards (93)
ThGM Cells in CNS Autoimmunity$390,000
R01 · FY2025 · AI · contact PI
IL-37: a novel regulator of inflammation in CNS autoimmunity$390,000
R01 · FY2025 · AI · contact PI
Role of IL-7R in CNS autoimmunity$378,300
R01 · FY2025 · AI · contact PI
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity$378,300
R01 · FY2025 · AI · contact PI
IL-37: a novel regulator of inflammation in CNS autoimmunity$390,000
R01 · FY2024 · AI · contact PI
ThGM Cells in CNS Autoimmunity$390,000
R01 · FY2024 · AI · contact PI
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity$390,000
R01 · FY2024 · AI · contact PI
Role of IL-7R in CNS autoimmunity$390,000
R01 · FY2024 · AI · contact PI
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity$390,000
R01 · FY2022 · AI · contact PI
ThGM Cells in CNS Autoimmunity$390,000
R01 · FY2022 · AI · contact PI
IL-37: a novel regulator of inflammation in CNS autoimmunity$390,000
R01 · FY2022 · AI · contact PI
Role of IL-7R in CNS autoimmunity$390,000
R01 · FY2022 · AI · contact PI
Role of IL-7R in CNS autoimmunity$390,000
R01 · FY2021 · AI · contact PI
ThGM Cells in CNS Autoimmunity$390,000
R01 · FY2021 · AI · contact PI
IL-37: a novel regulator of inflammation in CNS autoimmunity$390,000
R01 · FY2021 · AI · contact PI
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity$390,000
R01 · FY2021 · AI · contact PI
Mechanisms of GM-CSF effect in CNS autoimmune demyelination$390,000
R01 · FY2021 · AI · contact PI
Mechanisms of GM-CSF effect in CNS autoimmune demyelination$390,000
R01 · FY2020 · AI · contact PI
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity$390,000
R01 · FY2020 · AI · contact PI
Mechanisms of GM-CSF effect in CNS autoimmune demyelination$390,000
R01 · FY2019 · AI · contact PI
Mechanisms of GM-CSF effect in CNS autoimmune demyelination$390,000
R01 · FY2018 · AI · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R01 · FY2018 · AI · contact PI
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis$341,250
R01 · FY2018 · NS · contact PI
Mechanisms of GM-CSF effect in CNS autoimmune demyelination$390,000
R01 · FY2017 · AI · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R01 · FY2017 · AI · contact PI
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis$341,250
R01 · FY2017 · NS · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R01 · FY2016 · AI · contact PI
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis$341,250
R01 · FY2016 · NS · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R01 · FY2015 · AI · contact PI
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis$341,068
R01 · FY2015 · NS · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R01 · FY2014 · AI · contact PI
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis$339,063
R01 · FY2014 · NS · contact PI
Philadelphia Autoimmunity Center of Excellence$536,503
U19 · FY2013 · AI · contact PI
The Role of Dendritic Cells in Intravenous Tolerance$319,617
R01 · FY2013 · NS · contact PI
The Role of the TH17 cells in the pathogenesis of EAE$319,617
R01 · FY2013 · NS · contact PI
Investigation of Th 17 cells in Multiple Sclerosis$190,041
U19 · FY2013 · AI · contact PI
Administrative Core$63,309
U19 · FY2013 · AI · contact PI
Philadelphia Autoimmunity Center of Excellence$575,678
U19 · FY2012 · AI · contact PI
The role of IL-27 in iv tolerance in EAE$387,500
R56 · FY2012 · AI · contact PI
Anti-Inflammatory mechanisms of soybean-derived Bowman-Birk protease inhibitor$378,564
R01 · FY2012 · AT · contact PI
The Role of Dendritic Cells in Intravenous Tolerance$331,209
R01 · FY2012 · NS · contact PI
The Role of the TH17 cells in the pathogenesis of EAE$331,209
R01 · FY2012 · NS · contact PI
Investigation of Th 17 cells in Multiple Sclerosis$211,879
U19 · FY2012 · AI · contact PI
Administrative Core$71,630
U19 · FY2012 · AI · contact PI
Philadelphia Autoimmunity Center of Excellence$587,040
U19 · FY2011 · AI · contact PI
Anti-Inflammatory mechanisms of soybean-derived Bowman-Birk protease inhibitor$378,564
R01 · FY2011 · AT · contact PI
The Role of the TH17 cells in the pathogenesis of EAE$331,209
R01 · FY2011 · NS · contact PI
The Role of Dendritic Cells in Intravenous Tolerance$331,209
R01 · FY2011 · NS · contact PI
Investigation of Th 17 cells in Multiple Sclerosis$174,335
U19 · FY2011 · AI · contact PI
Administrative Core$88,713
U19 · FY2011 · AI · contact PI
Philadelphia Autoimmunity Center of Excellence$598,465
U19 · FY2010 · AI · contact PI
Anti-Inflammatory mechanisms of soybean-derived Bowman-Birk protease inhibitor$382,388
R01 · FY2010 · AT · contact PI
The Role of Dendritic Cells in Intravenous Tolerance$334,590
R01 · FY2010 · NS · contact PI
The Role of the TH17 cells in the pathogenesis of EAE$334,590
R01 · FY2010 · NS · contact PI
Investigation of Th 17 cells in Multiple Sclerosis$177,778
U19 · FY2010 · AI · contact PI
Administrative Core$90,511
U19 · FY2010 · AI · contact PI
Philadelphia Autoimmunity Center of Excellence$618,950
U19 · FY2009 · AI · contact PI
Anti-Inflammatory mechanisms of soybean-derived Bowman-Birk protease inhibitor$386,250
R01 · FY2009 · AT · contact PI
Tolerance induced by IV MBP in EAE$376,263
R01 · FY2009 · NS · contact PI
The Role of Dendritic Cells in Intravenous Tolerance$337,969
R01 · FY2009 · NS · contact PI
The Role of the TH17 cells in the pathogenesis of EAE$337,969
R01 · FY2009 · NS · contact PI
Investigation of Th 17 cells in Multiple Sclerosis$182,860
U19 · FY2009 · AI · contact PI
Administrative Core$94,818
U19 · FY2009 · AI · contact PI
Tolerance induced by IV MBP in EAE$376,263
R01 · FY2008 · NS · contact PI
Mechanisms of action IL-23 in relapsing demyelination$365,089
R01 · FY2008 · AI · contact PI
Role of IL-12/IL-23 in Intravenous Tolerance$317,280
R01 · FY2008 · NS · contact PI
Tolerance induced by IV MBP in EAE$376,263
R01 · FY2007 · NS · contact PI
Mechanisms of action IL-23 in relapsing demyelination$372,161
R01 · FY2007 · AI · contact PI
Role of IL-12/IL-23 in Intravenous Tolerance$317,280
R01 · FY2007 · NS · contact PI
Mechanisms of action IL-23 in relapsing demyelination$383,276
R01 · FY2006 · AI · contact PI
Tolerance induced by IV MBP in EAE$232,500
R01 · FY2006 · NS · contact PI
Role of IL-12/IL-23 in EAE$149,150
R01 · FY2006 · NS · contact PI
Role of IL-12/IL-23 in Intravenous Tolerance$1
R01 · FY2006 · NS · contact PI
Mechanisms of action IL-23 in relapsing demyelination$392,500
R01 · FY2005 · AI
Role of IL-12/IL-23 in Intravenous Tolerance$326,756
R01 · FY2005 · NS
Role of IL-12/IL-23 in EAE$298,300
R01 · FY2005 · NS
Mechanisms of action IL-23 in relapsing demyelination$392,500
R01 · FY2004 · AI
IL-12/IL-23 in Intravenous Tolerance$326,756
R01 · FY2004 · NS
Role of IL-12/IL-23 in EAE$298,300
R01 · FY2004 · NS
Role of IL-12/IL-23 in EAE$298,300
R01 · FY2003 · NS
TOLERENCE INDUCED BY I.V. MBP IN EAE$274,750
R01 · FY2003 · NS
PENN AUTOIMMUNITY CENTER OF EXCELLENCE$914,654
U19 · FY2002 · AI
TOLERENCE INDUCED BY I.V. MBP IN EAE$302,375
R01 · FY2002 · NS
PENN AUTOIMMUNITY CENTER OF EXCELLENCE$111,687
U19 · FY2002 · AI
Role of IL12 in the pathogenesis &therapy of CNS demyelination$0
U19 · FY2002 · AI
PENN AUTOIMMUNITY CENTER OF EXCELLENCE$888,012
U19 · FY2001 · AI
TOLERENCE INDUCED BY I.V. MBP IN EAE$302,375
R01 · FY2001 · NS
Role of IL12 in the pathogenesis &therapy of CNS demyelination$0
U19 · FY2001 · AI
PENN AUTOIMMUNITY CENTER OF EXCELLENCE$862,148
U19 · FY2000 · AI
SPECIFIC IMMUNOTHERAPY OF EAE BY CYTOTOXIC IMMUNOCONJUGATES$320,794
P01 · FY2000 · NS
TOLERENCE INDUCED BY I.V. MBP IN EAE$277,375
R01 · FY2000 · NS
Role of IL12 in the pathogenesis &therapy of CNS demyelination$233,266
U19 · FY2000 · AI
ETIOLOGY AND PATHOGENESIS OF MULTIPLE SCLEROSIS$62,401
P01 · FY2000 · NS